Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XmAb412 in healthy adult participants
NCT07713485Phase 1Recruiting
- Sponsor
- Xencor
- Start
- Jul 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of XmAb412 (4 arms), sponsored by Xencor. Primary endpoint: Incidence and severity of treatment emergent adverse events and serious adverse events at 28 weeks. Started Jul 2026; status: recruiting.
02
Drugs
XmAb412
Beyond the preview
Go deeper on NCT07713485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07713485.